Charles River Laboratories International, Inc. CRL
NYSE · Healthcare · Medical - Diagnostics & Research
$314.32
Close on Fri, 20 Nov 2026 · market value $15.1B
What the price is betting on
Priced for a lot to go rightAt $314, the price assumes revenue grows about 21% a year for five years, from $4B to about $9B by FY2030. That is about six times what analysts expect for the next two years and well above the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 10% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than CRL? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$118
Base
$132
Bull
$146
Today $314
- Bear $118. Cash flow grows 3% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $132. Cash flow grows 5% a year for the next 5 years, as analysts expect, then slows to long-run growth.
- Bull $146. Cash flow grows 7% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$4.2B$3.9B, below the path
- FY2027$5.1B$4.1B, below the path
- FY2028$6.1B$4.3B, below the path
- FY2029$7.4B$4.6B, below the path
- FY2030$9B$5.1B, below the path
Each year's revenue at 21% growth from $4B in the 12 months to September 2026.
At a glance
Healthcare · Medical - Diagnostics & Research · listed on NYSE
- Revenue, FY2025
- $4B
- Growth, 3 years a year
- −1.4%
- Cash margin
- 13%
- Net debt
- $2.9B
- Shares, 3-year change
- −3.6%
- Dividend yield
- 0%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.